NCT01001195 - Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

AGN-210669 ophthalmic solution, 0.1%

One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

DRUG

AGN-210669 ophthalmic solution, 0.075%

One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

DRUG

AGN-210669 ophthalmic solution, 0.05%

One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

DRUG

bimatoprost ophthalmic solution 0.03%

One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

Trial Locations (1)

Unknown

Rochester